Who is sponsoring NCT00292695?

NCT00292695 is sponsored by National Health Research Institutes, Taiwan.

What drugs are being tested in NCT00292695?

Interventions in NCT00292695: VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT.

Is NCT00292695 still recruiting?

NCT00292695 is currently completed. Last updated 28 October 2013.

Last reviewed 2013-10-28 · How we verify

NCT00292695

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of Concurrent Chemoradiation for The Localized Nasal NK/T-cell Lymphoma

Completed Phase 2 Last updated 28 October 2013

What this trial tests

Phase 2 trial testing VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT in Lymphoma in 33 participants. Completed in 1 December 2010.

Timeline

1 May 2006

Primary endpoint
1 December 2009

1 December 2010

Quick facts

Lead sponsor	National Health Research Institutes, Taiwan
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 May 2006
Primary completion	1 December 2009
Estimated completion	1 December 2010
Sites	1 location across Taiwan

Drugs / interventions tested

VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

National Health Research Institutes, Taiwan

Who can join

Under 70, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

tumor response by CT scan or MRI
Time frame: the first course of DVIP, one month after the last course of DVIP

Sponsor's own description

To determine whether adding combinational chemotherapy concurrently to conventional radiation will improve the response rate, event-free survival, and overall survival. To test the dose intensity and toxicity of chemotherapy in concurrence with radiation. To detect the blood EBV DNA level in Chinese Nasal NK/T-cell lymphoma patients and correlate to the treatment response and prognosis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma.
Tsai HJ, Lin SF, Chen CC, Chen TY, et al · · 2015 · cited 25× · PMID 24957163 · DOI 10.1111/ejh.12405
The war between the immune system and the tumor - using immune biomarkers as tracers.
Yang K, Lu R, Mei J, Cao K, et al · · 2024 · cited 9× · PMID 38816871 · DOI 10.1186/s40364-024-00599-5

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other National Health Research Institutes, Taiwan trials

Trials by the same sponsor.

NCT07579832 — Quantitative Monitoring of Disability Care Quality for Long-Term Care Facilities 2 · NA · not yet recruiting
NCT06981637 — Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Contr · Phase 2 · recruiting
NCT07177365 — Internet-Based Cognitive Behavioral Therapy With Treatment as Usual for Generalized Anxiety Disorder and Major Depressiv · NA · not yet recruiting
NCT07138261 — Taiwanese Anaplastic Thyroid Cancer Registry · not yet recruiting
NCT07151365 — Plant-based Diets and Healthy Aging · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00292695 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Health Research Institutes, Taiwan
Last refreshed: 28 October 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00292695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing